High molecular weight kininogen deficiency
|
0.770 |
Biomarker
|
disease |
BEFREE |
Remarkably, kininogen deficiency did not modify HDM-induced eosinophil/neutrophil influx, T helper 2 responses, mucus production, or lung pathology. kininogen ASO treatment started after HDM sensitization reduced plasma kininogen levels by 75% and reproduced the phenotype of kininogen deficiency: kininogen ASO administration prevented the HDM-induced increase in Penh without influencing leukocyte influx, Th2 responses, mucus production, or lung pathology.
|
30358441 |
2019 |
High molecular weight kininogen deficiency
|
0.770 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Genome-wide association study with additional genetic and post-transcriptional analyses reveals novel regulators of plasma factor XI levels.
|
28053049 |
2017 |
High molecular weight kininogen deficiency
|
0.770 |
GermlineCausalMutation
|
disease |
ORPHANET |
Isolated high-molecular-weight kininogen deficiency: a novel frameshift mutation in exon 10.
|
17522339 |
2007 |
High molecular weight kininogen deficiency
|
0.770 |
Biomarker
|
disease |
BEFREE |
Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient: insights into structural requirements for kininogen expression.
|
12576314 |
2003 |
High molecular weight kininogen deficiency
|
0.770 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
We conclude that a single base mutation in the kininogen gene exon 5 was responsible for kininogen deficiency in the Williams family.
|
7901207 |
1993 |
High molecular weight kininogen deficiency
|
0.770 |
GeneticVariation
|
disease |
BEFREE |
We conclude that a single base mutation in the kininogen gene exon 5 was responsible for kininogen deficiency in the Williams family.
|
7901207 |
1993 |
High molecular weight kininogen deficiency
|
0.770 |
Biomarker
|
disease |
BEFREE |
This case reports the first description of Fitzgerald factor (high molecular weight kininogen) deficiency in Australia.
|
3574180 |
1987 |
High molecular weight kininogen deficiency
|
0.770 |
Biomarker
|
disease |
BEFREE |
Contents of coagulation factors in B/N Katholiek thus measured as well as the values of prekallikrein and HMW kininogen previously reported were summarized and suggested that B/N Katholiek rat could be similar deficiency as Fitzgerald trait.
|
6710438 |
1984 |
High molecular weight kininogen deficiency
|
0.770 |
Biomarker
|
disease |
BEFREE |
Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Evidence that high molecular weight kininogen and prekallikrein exist as a complex in normal human plasma.
|
893663 |
1977 |
High molecular weight kininogen deficiency
|
0.770 |
Biomarker
|
disease |
BEFREE |
Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis.
|
1245795 |
1976 |
High molecular weight kininogen deficiency
|
0.770 |
Biomarker
|
disease |
CTD_human |
|
|
|
High molecular weight kininogen deficiency
|
0.770 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
Hyperalgesia
|
0.560 |
AlteredExpression
|
phenotype |
BEFREE |
Synergistic expression of cyclooxygenase-2 (COX-2) by interleukin-1β (IL-1β) and bradykinin (BK) in peri-sensory neurons results in the production of prostanoids, which affects sensory neuronal activity and responsiveness and causes hyperalgesia.
|
30528878 |
2019 |
Hyperalgesia
|
0.560 |
Biomarker
|
phenotype |
BEFREE |
P2 × 7 receptor-induced articular hyperalgesia is sustained by the involvement of this purinergic receptor in bradykinin and dopamine-induced hyperalgesia in the knee joint.
|
29260240 |
2018 |
Hyperalgesia
|
0.560 |
Biomarker
|
phenotype |
BEFREE |
Dexamethasone (glucocorticoid anti-inflammatory agent), DALBK (bradykinin B1 antagonist), Atenolol (β1 adrenoceptor antagonist), ICI 118,551 (β2 adrenoceptor antagonist), indomethacin (cyclooxygenase inhibitor), and fucoidan (non-specific selectin inhibitor) all reduced static contraction-induced muscle hyperalgesia; however, the bradykinin B2 antagonist, bradyzide, did not have an effect on static contraction-induced muscle hyperalgesia.
|
28673715 |
2017 |
Hyperalgesia
|
0.560 |
Biomarker
|
phenotype |
BEFREE |
IS comprises an acidic combination of bradykinin, serotonin, histamine and prostaglandin PGE2 and was introduced to basic pain research as a tool to activate and sensitize peripheral nociceptors when studying pathological pain conditions associated with allodynia and hyperalgesia.
|
28167076 |
2017 |
Hyperalgesia
|
0.560 |
Biomarker
|
phenotype |
BEFREE |
Inflammatory mediators such as prostaglandin-E2 or bradykinin cause hyperalgesia by activating cellular kinases that phosphorylate TRPV1, a process that has recently been shown to rely on a scaffolding protein, AKAP79, to target the kinases to TRPV1.
|
23699529 |
2013 |
Hyperalgesia
|
0.560 |
Biomarker
|
phenotype |
BEFREE |
Heightened nociceptor function caused by inflammatory mediators such as bradykinin (BK) contributes to increased pain sensitivity (hyperalgesia) to noxious mechanical and thermal stimuli.
|
22921401 |
2012 |
Hyperalgesia
|
0.560 |
Biomarker
|
phenotype |
CTD_human |
Sex differences in behavior and expression of CGRP-related genes in a rodent model of chronic migraine.
|
21521205 |
2011 |
Hyperalgesia
|
0.560 |
Biomarker
|
phenotype |
RGD |
P2X3 and P2X2/3 receptors mediate mechanical hyperalgesia induced by bradykinin, but not by pro-inflammatory cytokines, PGE₂ or dopamine.
|
20868656 |
2010 |
Hyperalgesia
|
0.560 |
Biomarker
|
phenotype |
CTD_human |
Evidence of TRPV1 receptor and PKC signaling pathway in the antinociceptive effect of amyrin octanoate.
|
19646975 |
2009 |
Hyperalgesia
|
0.560 |
Biomarker
|
phenotype |
CTD_human |
Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia.
|
18234883 |
2008 |
Hyperalgesia
|
0.560 |
Biomarker
|
phenotype |
CTD_human |
In wild-type mice, activation of PKRs by the PKR agonist Bv8 caused hyperalgesia and sensitized to the actions of capsaicin. pkr1-null mice exhibited impaired responses to Bv8 but showed normal hyperalgesic responses to bradykinin and PGE2 (prostaglandin E2).
|
16793879 |
2006 |
Hyperalgesia
|
0.560 |
Biomarker
|
phenotype |
CTD_human |
In addition, the ME of B. microstachya (3--300 mg kg(-1), i.p., 30 min earlier) inhibited, in a graded manner, the hyperalgesia induced by bradykinin (3.2 microg/paw), substance P (13.5 microg/paw), carrageenan (300 microg/paw), capsaicin (100 microg/paw) and adrenaline (100 ng/paw) in the rat paw, with mean ID50 values of 20.5, 17.9, 101.8, 54.2 and 99.7 mg kg(-1), respectively.
|
16259764 |
2005 |
Hyperalgesia
|
0.560 |
Biomarker
|
phenotype |
CTD_human |
Antinociceptive properties of mixture of alpha-amyrin and beta-amyrin triterpenes: evidence for participation of protein kinase C and protein kinase A pathways.
|
15626726 |
2005 |